T1	p 54 97	previously untreated advanced breast cancer
T2	p 643 697	previously untreated metastatic breast cancer patients
T3	p 1258 1521	Patients had to have histologically documented measurable breast cancer and a performance status of 0-1 . Patients could not have had prior chemotherapy for metastatic disease . Prior adjuvant chemotherapy was permitted . Patients could not have visceral crisis .
T4	p 2284 2327	previously untreated breast cancer patients
T5	i 6 15	Amonafide
T6	i 154 163	Amonafide
T7	i 498 507	Amonafide
T8	i 797 840	cyclophosphamide-doxorubicin-5-fluorouracil
T9	i 883 926	cyclophosphamide-doxorubicin-5-fluorouracil
T10	i 1133 1142	amonafide
T11	i 1186 1229	cyclophosphamide-doxorubicin-5-fluorouracil
T12	i 1522 1531	Amonafide
T13	i 2252 2261	amonafide
T14	o 988 1030	survival , toxicity , and overall response
T15	o 1734 1742	Toxicity
T16	o 1807 1817	leukopenia
T17	o 1844 1860	thrombocytopenia
T18	o 1875 1885	leukopenia
T19	o 1902 1918	thrombocytopenia
T20	o 1925 1938	response rate
T21	o 2014 2036	hematological toxicity
T22	o 2083 2093	leukopenia
T23	o 2176 2192	thrombocytopenia
T24	o 2450 2468	Rates of responses